SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
SCYNEXIS completed its Phase 1 SAD/MAD study of intravenous SCY-247, reporting the drug was generally well tolerated with no drug-related serious adverse events across 56 healthy participants. Once-daily IV doses of 50 mg or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis, and the company plans to initiate Phase 2 in oral and IV formulations in 2027, subject to FDA agreement.
Key figures
- Drug Name
- SCY-247 (intravenous formulation)
- Phase Of Trial
- Phase 1
- Cash runway
- into 2029
- Cohort split
- 42 SCY-247 / 14 placebo
- Phase 2 start
- 2027
- Efficacy target
- AUC(0-24) of 20 µg·h/mL
- Barda funding up to
- $214 million
- Participants enrolled
- 56
- Max single dose tested
- 300 mg
- Max multiple dose tested
- 200 mg once daily for 7 days
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.